Pascal Deschatelets - Jul 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Scientific Officer
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol: APLS
Transactions as of: Jul 8, 2022
Transactions value $: -$526,005
Form type: 4
Date filed: 7/12/2022, 04:04 PM
Previous filing: Jun 22, 2022
Next filing: Aug 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$32K	+12K	+1.29%	$2.67^*	943K	Jul 8, 2022	Direct	F1
transaction	APLS	Common Stock	Options Exercise	$17.4K	+6.5K	+0.69%	$2.67^*	950K	Jul 8, 2022	Direct	F2
transaction	APLS	Common Stock	Sale	-$575K	-12K	-1.26%	$47.95	938K	Jul 8, 2022	Direct	F1

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-12K	-3.83%	$0.00	301K	Jul 8, 2022	Common Stock	12K	$2.67	Direct	F1, F3
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-6.5K	-2.16%	$0.00	295K	Jul 8, 2022	Common Stock	6.5K	$2.67	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2	This is a scheduled exercise from 10B5-1 trading plan.
F3	This stock option was granted on 12/5/2013 and is fully vested.